Epidemiology DataMay 2022

IMPORTANT NOTICE
For the purposes of this notice, “presentation” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical
Company Limited (“Takeda”) regarding this presentation. This presentation (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent orform part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any
jurisdiction. No shares or other securities are being offered to the public by means of this presentation. No offering of securities shall be made in the United States except pursuant to registration under the U.S.
Securities Act of 1933, as amended, or an exemption therefrom. This presentation is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by
the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation ofapplicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this presentation, “Takeda” is sometimes used for convenience where references are made to Takeda and its
subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served
by identifying the particular company or companies.
The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.

This presentation contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths.
Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

1 |OVERVIEW OF EPIDEMIOLOGY DATAONCOLOGYGASTROENTEROLOGY (GI)RARE GENETIC & HEMATOLOGY2 |EPIDEMIOLOGY – NINLARO, ALUNBRIG, ADCETRIS & ICLUSIG
Total Global Eligible
Population (March 2022)

Geographies included

R/R 2L+ Multiple Myeloma~114,0001

Japan, US, EU5, China

ALK+ NSCLC~36,0002

Japan, US, EU5, China

HL – Front Line, ASCT
Consolidation, 2L+; TCL - PTCL &R/R CTCL

~22,0003

Japan, EU5, China

2L+ CML, ALL~5,2004

US2L+ EGFR Exon20 Insertion+ NSCLC~6,2005

Japan, US, EU5Product3 | 1.

IndicationR/R 2L+ MM label eligible patients; 2. ALK+ tested patients; 3. CD30+ label eligible patients - regulatory approval includes Stage IV/ITT Front Line Patients and High Risk HL consolidation patients; 4. 2L+ CP-CML, 3L+ AP/BP-CML, T315I+ CML, Ph+ ALL 5. EGFR
Exon20 insertion+ mNSCLC patients whose disease has progressed on or after platinum-based chemotherapy.
Source: Takeda estimates. EU5 = France, Spain, Germany, Italy, UKOVERVIEW OF EPIDEMIOLOGY DATAONCOLOGYGASTROENTEROLOGY (GI)RARE GENETIC & HEMATOLOGY

4 |EPIDEMIOLOGY ULCERATIVE COLITIS (UC)
Japan
GEM

~3,760K
329K(incl. China)~3,300K

EUCAN

315K

US

1,434K
1,291K

1,207K

924K

~420K
28K

786K

770K

93K
179K
119K

Diagnosed Prevalence

TreatedPatients on biologic therapies

5 | Source: Takeda estimates. Note: Numbers are rounded.

EPIDEMIOLOGY CROHN’S DISEASE (CD)
Japan
GEM

~2,370K
58K~2,110K

413K(incl. China)

EUCAN

57K

US

372K

1,053K
878K

~680K
122K

847K

804K

32K

280K
247K

Diagnosed Prevalence
6 | Source: Takeda estimates. Note: Numbers are rounded.

TreatedPatients on biologic therapies

EPIDEMIOLOGY COMPLEX CROHN'S PERIANAL FISTULA (CPF)~1,960K
Japan

58K

EUCAN
US
1,053K

847K

~324K
119K

178K
Crohn’s Disease (CD)Patients

7 | Source: Takeda estimates. Note: Numbers are rounded.

CD Patients withPerianal Fistula

27K

~213K
60K

14K
139K

Complex Perianal Fistula(CPF) Patients

OVERVIEW OF EPIDEMIOLOGY DATAONCOLOGYGASTROENTEROLOGY (GI)RARE GENETIC & HEMATOLOGY

8 |EPIDEMIOLOGY HEREDITARY ANGIOEDEMA

Global70K

24K

Prevalence

9 | Source: Takeda estimates. Note: Numbers are rounded.

Diagnosed

20K
TreatedEPIDEMIOLOGY GAUCHER’S DISEASE:GLOBAL, CHINA/INDIA NOT INCLUDED~24K un-diagnosed
patients (70%)~34-35K prevalentpatients~10K diagnosed
patients (30%)

Prevalence
10 | Source: Takeda estimates. Note: Numbers are rounded.

Diagnosis

EPIDEMIOLOGY FABRY’S DISEASE:
EX-US REGION, CHINA/INDIA NOT INCLUDED~40K un-diagnosed
patients (74%)~53-54K prevalent
Fabry patients~14K diagnosed
Fabry patients(26%)

Prevalence

11 | Source: Takeda estimates. Note: Numbers are rounded.

Diagnosis

EPIDEMIOLOGY HUNTER’S DISEASE:GLOBAL, INDIA/CHINA NOT INCLUDEDMPS II Patients
Global5K

2-3K

Prevalence

12 | Source: Takeda estimates. Note: Numbers are rounded.

Diagnosed

2K

TreatedEPIDEMIOLOGY HEMOPHILIA A
Hemophilia A without inhibitors
~142K
~116K
69K

~92K
46K

5K

5K

Japan

40K

EUCAN

5K

US

50K

48K

18K

17K

17K

Prevalence

Diagnosed

Treated13 | Source: Takeda estimates. Note: Numbers are rounded.

GEM excl. CN/IN

30K

EPIDEMIOLOGYCYTOMEGALOVIRUS (CMV) INFECTION IN POST-TRASPLANTRARE

1/41 of transplant patients experience CMV infections
183k

Legend:≈99k

GlobalHeartKidneyLungLiverPancreas

65.0%

23.0%

6.0%

4.0%

≈34k

2.0%

≈50k

Adult Transplantations
Performed Annually14 |Source: Takeda estimates. Note: Numbers are rounded.

Solid Organ Transplants

Allogeneic Hemopoietic
Stem Cell Transplant

Autologous Hemopoietic
Stem Cell Transplant